Loading stock data…
PGNY
$18.60+0.02 (+0.11%)
After Hours$18.60+0.00 (+0.00%)· Last close May 1
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Progyny, Inc. in the Healthcare sector is trading at $18.60. The stock is currently near its 52-week low of $16.10, remaining 14.9% below its 200-day moving average. Technical signals show overbought RSI of 72 and bullish MACD crossover, explaining why PGNY maintains its current current market pressure. The Whystock Score of 10/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 72) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$18.60
Potential Downside
27.5%
Whystock Fair Value$13.48
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Buy
Mean target$27.45+47.6%
Range$19.00 – $31.00
Fundamentals
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cyc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.47B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
27.68
Beta
Defensive asset. Lower volatility than the S&P 500.
0.99
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.29%
Volume
Today's trading volume
1.72M
Recent News
Should Value Investors Buy Progyny (PGNY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Progyny (PGNY) Upgraded to Buy: Here's Why
Progyny (PGNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PGNY or ALHC: Which Is the Better Value Stock Right Now?
PGNY vs. ALHC: Which Stock Is the Better Value Option?
2 Reasons to Sell PGNY and 1 Stock to Buy Instead
Although the S&P 500 is down 2.1% over the past six months, Progyny’s stock price has fallen further to $17.17, losing shareholders 16.6% of their capital. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
Is Progyny (PGNY) Now An Opportunity After Steep Share Price Pullback?
If you are trying to figure out whether Progyny's current share price reflects its underlying worth, the key question is what you are really paying for at US$16.60 a share. The stock has recently been under pressure, with returns of a 3.9% decline over 7 days, a 5.8% decline over 30 days, and a 35.5% decline year to date, contributing to a 26.5% decline over 1 year and a 46.8% decline over 3 years. These moves have come as investors reassess the company and the broader healthcare space, with...